Boehringer In­gel­heim backs Max Planck spin­out in tak­ing a shot at tough class of can­cer tar­gets

Sci­en­tists have long known about tu­mor-as­so­ci­at­ed car­bo­hy­drate anti­gens — those ab­nor­mal sac­cha­rides that are abun­dant on can­cer cell sur­faces and feed them on — but their abil­i­ty to hide from the im­mune sys­tems means they have proved to be eva­sive tar­gets in im­muno-on­col­o­gy.

Two gly­co­sciences ex­perts at the Max Planck In­sti­tute in Ger­many be­lieved syn­the­siz­ing those tar­gets in the first place is key to crack­ing that prob­lem. They have now re­ceived a mod­est seed round to pur­sue that idea at their Berlin-based biotech spin­out, Taca­lyx.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.